GoAI
Get started
Beam Therapeutics Inc. logo

Beam Therapeutics Inc.

BEAM

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$28.40

Market data unavailable

Aug 24, 10:15 AM ET

BEAM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

56

Fair Value

Momentum

64

Gaining

Sentiment

67

Bullish

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Volume
211.88K
Market cap
2.95B USD

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends186%-157%-500%-843%Gross margin, FY2021: -347.75%Gross margin, FY2022: -411.48%Gross margin, FY2023: 100.00%Gross margin, FY2024: -478.67%Gross margin, FY2025: 84.05%Operating margin, FY2021: -757.01%Operating margin, FY2022: -555.61%Operating margin, FY2023: -46.73%Operating margin, FY2024: -654.25%Operating margin, FY2025: -274.57%Net margin, FY2021: -714.91%Net margin, FY2022: -474.54%Net margin, FY2023: -35.09%Net margin, FY2024: -593.13%Net margin, FY2025: -57.24%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -347.75%. Gross margin FY2022 -411.48%. Gross margin FY2023 100.00%. Gross margin FY2024 -478.67%. Gross margin FY2025 84.05%. Operating margin FY2021 -757.01%. Operating margin FY2022 -555.61%. Operating margin FY2023 -46.73%. Operating margin FY2024 -654.25%. Operating margin FY2025 -274.57%. Net margin FY2021 -714.91%. Net margin FY2022 -474.54%. Net margin FY2023 -35.09%. Net margin FY2024 -593.13%. Net margin FY2025 -57.24%.

Income trends

Revenue

139.74M USD+120.01%

Operating income

−383.69M USD+7.67%

Net income

−79.99M USD+78.77%
Income trends across reported periods457.04M USD139.73M USD−177.58M USD−494.9M USDRevenue, FY2021: 51.84M USDRevenue, FY2022: 60.92M USDRevenue, FY2023: 377.71M USDRevenue, FY2024: 63.52M USDRevenue, FY2025: 139.74M USDOperating income, FY2021: −392.47M USDOperating income, FY2022: −338.48M USDOperating income, FY2023: −176.49M USDOperating income, FY2024: −415.57M USDOperating income, FY2025: −383.69M USDNet income, FY2021: −370.64M USDNet income, FY2022: −289.09M USDNet income, FY2023: −132.53M USDNet income, FY2024: −376.74M USDNet income, FY2025: −79.99M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 51.84M USD. Revenue FY2022 60.92M USD. Revenue FY2023 377.71M USD. Revenue FY2024 63.52M USD. Revenue FY2025 139.74M USD. Operating income FY2021 −392.47M USD. Operating income FY2022 −338.48M USD. Operating income FY2023 −176.49M USD. Operating income FY2024 −415.57M USD. Operating income FY2025 −383.69M USD. Net income FY2021 −370.64M USD. Net income FY2022 −289.09M USD. Net income FY2023 −132.53M USD. Net income FY2024 −376.74M USD. Net income FY2025 −79.99M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue139.74M USD63.52M USD377.71M USD60.92M USD51.84M USD
Cost of goods sold22.29M USD367.56M USD—311.59M USD232.13M USD
Gross profit117.45M USD−304.04M USD377.71M USD−250.67M USD−180.29M USD
Research and development409.62M USD367.56M USD437.38M USD311.59M USD387.09M USD
Selling, general, and administrative113.82M USD111.53M USD116.81M USD87.81M USD57.22M USD
Operating expenses501.14M USD111.53M USD554.19M USD87.81M USD212.18M USD
Interest income—49.09M USD46.68M USD15.3M USD—
Interest expense43.73M USD————
Depreciation and amortization6.34M USD21.93M USD29.53M USD14.15M USD7.45M USD
Operating income−383.69M USD−415.57M USD−176.49M USD−338.48M USD−392.47M USD
Net income−79.99M USD−376.74M USD−132.53M USD−289.09M USD−370.64M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+32.64%
11 comparable reports
Latest EPS result
-1.18
Estimate -1.11 · Miss by 6.31%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.08-0.5-0.92-1.34Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual -1.09, estimate -1.25, surprise +12.80%, Beat. Q2 2025, reported May 6, 2025: actual -1.24, estimate -1.11, surprise -11.71%, Miss. Q3 2025, reported Aug 5, 2025: actual -1, estimate -1.04, surprise +3.85%, Beat. Q4 2025, reported Nov 4, 2025: actual -1.1, estimate -0.98, surprise -12.24%, Miss. Q1 2026, reported Feb 24, 2026: actual -0.1, estimate -1.13, surprise +91.15%, Beat. Q2 2026, reported May 7, 2026: actual -0.91, estimate -0.87, surprise -4.60%, Miss. Q3 2026, reported Aug 4, 2026: actual -1.18, estimate -1.11, surprise -6.31%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate -1.16, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates123.2M82.27M41.34M416.5KQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 30.07M USD, estimate 16.47M USD, surprise +82.51%, Beat. Q2 2025, reported May 6, 2025: actual 7.47M USD, estimate 15.52M USD, surprise -51.86%, Miss. Q3 2025, reported Aug 5, 2025: actual 8.47M USD, estimate 11.54M USD, surprise -26.62%, Miss. Q4 2025, reported Nov 4, 2025: actual 9.7M USD, estimate 13.22M USD, surprise -26.61%, Miss. Q1 2026, reported Feb 24, 2026: actual 114.11M USD, estimate 11.67M USD, surprise +877.88%, Beat. Q2 2026, reported May 7, 2026: actual 31.74M USD, estimate 10.98M USD, surprise +189.13%, Beat. Q3 2026, reported Aug 4, 2026: actual 490K USD, estimate 16.37M USD, surprise -97.01%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate 8.72M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$48.33

68.75% upside
Past 12 months12-month forecastHigh $80.00Average $48.33Low $26.00

Rating distribution

27 ratings
Strong buy00%
Buy1867%
Hold830%
Sell14%
Strong sell00%

Recent analyst actions

12 institutions
CitigroupmaintainBuy

BEAM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research BEAM

research.disclaimer